SANTA MONICA, Calif., Oct. 2, 2017 /PRNewswire/ -- Parallax Health Sciences, Inc. ("Parallax" or the "Company") (OTC-Pink:
Donald established, as founder and CEO of Quality Behavioral Outcomes, Inc., one of the first "school based" consulting firms dedicated to Applied Behavioral Analysis employing 600+ employees by 2009 when he sold the company.
Donald's "Quality Behavioral Outcomes" Applied Behavior systems platform was used to launch "Trumpet Behavioral Health in 2009 and where Donald served as Trumpet's Executive Director and Clinical Advisor until 2012. Trumpet maintains a reputation as one of the largest & most premier Behavioral Health providers in the USA.
"Having founded several successful Behavioral Health companies in the USA and UK, Donald understands how to bridge the science of behavior and its practice to achieve meaningful and socially significant outcomes. He has dedicated his entire career to improving the "life quality" of those he serves," stated Nathaniel Bradley, Parallax Behavioral Health Director and CTO.
Mr. Wachelka will be charged with the development of the Company's proprietary software for the mass commercialization and business operations dedicated to Parallax Behavioral Health's proven and recently acquired Goal Mastery Platform known as REBOOT. Reliable Evidenced Based Outcomes Optimization Technologies (R.E.B.O.O.T.) is a technology platform specifically designed to Improve Health Treatment Outcomes using Proprietary Behavior technology systems. With his team at Parallax Behavioral Health, a mobile platform and application now known as "MyPath," a mobile application software that will leverage the capabilities of the R.E.B.O.O.T. within prescribed treatment regimens and known actionable interventional processes.
"I am extremely excited about the possibilities for commercial deployment of our R.E.B.O.O.T technology platform and MyPath Mobile Apps into the marketplace. The idea of a patent pending proprietary technology and system with proven clinical data that delivers Reliable Evidence Based Optimization Outcomes to the patients and health providers is a tool that will redefine the achievement of goals of patients under behavioral health care. The cost of health care is unsustainable. The industry is putting pressure on health care providers to focus on outcomes of treatment and not just the treatment. I believe with R.E.B.O.O.T and MyPath we have the capability to significantly increase these outcomes. We are positioned to deliver a cost effective approach to improving patient care on a large scale. This is truly a game changer," stated Donald Wachelka.
About Parallax Behavioral Health, Inc. ("Parallax Behavior")
Parallax Behavioral Health is a wholly owned subsidiary of Parallax Health Sciences, Inc. ("PARALLAX") that includes RoxSan Pharmacy, Inc. a Beverly Hills, CA based Compound and Fertility Specialty Pharmacy licensed in 37 States in the continental US; Parallax Diagnostics, Inc. a Santa Monica, CA based point of care diagnostic business and Parallax Health Management, Inc., a technology systems integrations company and home health hub with a first of its kind patented technology to support remote patient monitoring, medication adherence and tele-medicine.
Parallax Behavioral Health is the newest subsidiary within the Parallax Health Sciences portfolio and is a critical business unit to its overarching comprehensive healthcare strategy.
With its patent pending technology (R.E.B.O.O.T), which encompasses predictive, progressive behavior analytics and goal optimization software, and its Mobile App series "MyPath", PBH is strategically positioned to enable large healthcare corporations to individuals take control of their health outcomes.
Health Organizations for the first time will have the opportunity to "scale" their patient adherence programs while having visibility into its effectiveness and bottom line impact.
Individual users will have a goal wizard, virtual coach and rules engine that will help create a personal path toward wellness. With personalized analysis, decision support and "goal" mastery feedback, the individual will be primed, guided and motivated to adhere to their treatment plan.
Parallax Health Sciences, Inc. ("Parallax"), is a publicly traded innovative biomedical healthcare company delivering consumer-centric products and services in the areas of pharmaceuticals, digital health and remote patient monitoring, behavioral health and point of care diagnostics. In addition to Parallax Behavior, Parallax operates Parallax Health Management, Inc. ("PHM") a Tucson Arizona based digital health and systems integration company, focused on delivering Remote Patient Monitoring and Telehealth solutions, through proprietary technology platforms, Roxsan Pharmacy, Inc. ("Roxsan") a Beverly Hills, California based Compound and Infertility Pharmacy and Parallax Diagnostics, Inc. (PRLX-DIAG") an innovative point of care diagnostic company with patented testing platform and FDA Cleared tests.
This release includes forward-looking statements contained within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements regarding Parallax's expected future financial position, results of operations, cash flows, financing plans, business strategy, products and services, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include words such as "anticipate," "if," "believe," "plan," "estimate," "expect," "intend," "may," "could," "should," "will," and other similar expressions, are forward-looking statements. All forward-looking statements involve risks, uncertainties and contingencies, many of which are beyond Parallax's control, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. Factors that may cause actual results to differ materially from those in the forward-looking statements include those set forth in Parallax's Form 10-K and other report filings with the SEC. Parallax is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
For more information please visit our website at www.parallaxhealthsciences.com or www.roxsan.com Or email email@example.com
View original content:http://www.prnewswire.com/news-releases/parallax-health-sciences-inc-selects-donald-a-wachelka-ma-bcba-as-the-president-of-its-behavioral-health-unit-300528915.html
SOURCE Parallax Health Sciences, Inc.
Subscribe to our Free Newsletters!
Fallopian tube cancer is a form of gynecologic cancer arising in the fallopian tubes, which are ...
Cushing syndrome is a collection of symptoms caused due to excessive amount of cortisol in the body ...
CAR T-cell therapy is a type of gene therapy where the patient's T-lymphocytes are genetically ...View All